Clinician education regarding AD, cognitive assessment, amyloid confirmation with PET or CSF, ARIA detection and management, infusion and infusion reactions, APOE genotyping, and patient communication are foundational for success in lecanemab treatment programs. The gene discussed is APOE; the disease is Alzheimer disease.